2024-12-05 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis Report

**1. Performance Comparison & Divergence:**

Eli Lilly and Co (LLY), a pharmaceutical company specializing in innovative medicines, significantly outperformed the S&P 500 (VOO) over the measured period.  The cumulative return for LLY is 642.58%, while the S&P 500's is 129.75%. This results in a raw return difference of 512.8 percentage points.  The relative divergence of 76.1% indicates that LLY's performance is in the upper range of its historical performance relative to the S&P 500.  The provided CAGR data further supports this substantial outperformance, consistently exceeding the implied S&P 500 returns across all periods.  Alpha consistently shows near zero, suggesting the outperformance may be attributed primarily to the stock's higher beta.


**2. Recent Price Movement:**

* **Closing Price:** $813.33
* **5-Day Moving Average:** $797.20
* **20-Day Moving Average:** $782.28
* **60-Day Moving Average:** $859.99

The stock is currently trading below its 5, 20, and 60-day moving averages, suggesting a potential short-term downtrend.  The last market price of $836.16 shows a recent decline.


**3. Technical Indicators & Expected Return:**

* **RSI:** 48.9 – Near neutral territory, suggesting neither overbought nor oversold conditions.
* **PPO:** 1.16 – Positive, indicating bullish momentum.
* **Relative Divergence Change (20-day):**  NaN (-) suggests a recent short-term downward trend.
* **Expected Return:** 562.1% –  This represents a significant potential long-term (2+ years) outperformance against the S&P 500 given a continued similar trajectory.  The high value needs to be assessed in context of the high risk associated with such high returns and associated volatility.  The large difference between the last market price ($836.16) and the closing price used in the calculations needs to be investigated.


**4. Recent Earnings Analysis:**

The provided earnings data shows significant variability in EPS and relatively stable revenue.

* **EPS Trends:**  EPS fluctuated widely across the quarters, with a substantial decrease in the 2023-11-02 and 2024-10-30 reports.  This highlights volatility in earnings and makes any trend identification difficult without further context.
* **Revenue Growth Trends:** Revenue remains relatively stable with minor fluctuations. While not exhibiting strong growth, it demonstrates relative consistency.  There is no clear upward or downward revenue trend evident.
* **Quarterly Comparison:** Revenue and EPS exhibit notable variations between quarters, requiring further analysis to understand the underlying drivers of these changes.  There's no information provided to assess performance against expectations.

**5. Financial Information Analysis:**

The financial data shows high and relatively stable profit margins, though there is volatility in the ROE.

* **Revenue and Profitability:**  Strong and consistent profit margins, ranging from 80.42% to 81.02% over the reported period.  Revenue shows relatively stable performance.
* **Capital and Profitability:**  Equity growth is observed but ROE fluctuates significantly, possibly reflecting changes in earnings or capital structure.  The negative ROE in 2023-09-30 requires further investigation.

**6. News and Recent Issues:**

No specific news or recent market outlook information is provided for the analysis of the past two days. Analyst opinions and performance highlights are also missing.


**7. Overall Analysis:**

LLY has demonstrated exceptional historical outperformance compared to the S&P 500. The significant divergence and high CAGR suggest a strong upward trend.  However, recent price action indicates a potential short-term downturn.  While financial data shows strong profit margins, recent earnings reports highlight considerable EPS volatility, requiring more detailed analysis to fully understand these fluctuations. The lack of current news and analyst sentiment information hinders a complete assessment. The extremely high expected return of 562.1% needs careful consideration given the volatility inherent in such high growth stocks.


**8. Disclaimer:**

This report is for informational purposes only and does not constitute financial advice.  Investment decisions should be based on thorough due diligence and consideration of individual risk tolerance.  The analysis is limited by the data provided and may not reflect the complete financial picture of Eli Lilly and Co.  Missing data points (like analyst expectations and recent news) limit the scope of this analysis.
